Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Progress in circRNA-Based Therapy in Experimental Parkinson’s Disease

Open access
Titze-de-Almeida, Simoneide Souza Souza, Titze-de-Almeida, Ricardo · 2023 · Pharmaceutics

Preprint — published as 10.3390/pharmaceutics15082035

Abstract

Circular RNAs (circRNAs) are single-stranded RNA molecules often circularized by backsplicing. Growing evidence implicates circRNAs in the underlying mechanisms of various diseases, such as Alzheimer's and Parkinson's disease (PD) - the first and second most prevalent neurodegenerative disorders. Several circRNAs are associated with brain damage, including circSNCA, circHIPK2, circHIPK3, and circSLC8A1. Gain-of-function and loss-of-function studies on circRNAs have shed light on their roles in the pathobiology of various diseases. Gain-of-function approaches typically employ viral or non-viral vectors that hyperexpress RNA sequences capable of circularizing to form the specific circRNA under investigation. In contrast, loss-of-function studies utilize CRISPR/Cas systems, antisense oligonucleotides (ASOs), or RNAi techniques to knockdown the target circRNA. Given that aberrantly expressed circRNAs have been associated with brain pathologies, a critical question arises: could circRNAs serve as viable targets for neuroprotective treatments? Translating any oligonucleotide-based therapy, including those targeting circRNAs, involves developing adequate brain delivery systems, minimizing off-target effects, and addressing the high costs of treatment. Nonetheless, RNAi-based FDA-approved drugs have entered the market, and circRNAs have attracted significant attention and investment from major pharmaceutical companies. Spanning from bench to bedside, circRNAs present a vast opportunity in biotechnology for oligonucleotide-based therapies designed to slow or even halt the progression of neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.20944/preprints202306.1406.v1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of circRNA biogenesis. Precursor mRNA (pre-mRNA) is the primary RNA transcript synthesized on a DNA template in the cell nucleus. Pre-mRNA can follow two distinct cellular pathways. In the upward direction, pre-mRNA gives rise to 5′-3′ mRNA sequences through canonical splicing (a), which removes introns and generates a molecule to be exported to the cytoplasm for guiding protein synthesis. In the alternate downward direction, pre-mRNA produces circRNAs through back-splicing reactions (b). Intronic circRNAs (ciRNA) (c) are formed by a lariat-driven cyclization process that exclusively involves introns. Specific sequence elements adjacent to an exon, rich in guanine (G) and uracil (U) (depicted in blue), bind to an 11-nucleotide cytosine (C)-rich sequence (shown in red) near another exon. This binding allows evasion of the debranching reaction and prevents degradation by exonucleases. Reverse complementary sequences and/or RNA-binding proteins (RBP) (d) act to bring the nucleotide sequences into close proximity. This process facilitates the back-splicing reaction, leading to the generation of exonic circRNA (EciRNA) (e) or exon-intron circRNA (EIciRNA) (f). Abbreviations: mRNA, messenger RNA; pre-mRNA, precursor mRNA; ciRNA, intronic circRNA; EciRNA, exonic circRNA; EIciRNA, exon-intron circRNA; E, exon; I, intron; RBP, RNA-binding proteins.
Figure 1 Schematic representation of circRNA biogenesis. Precursor mRNA (pre-mRNA) is the primary RNA transcript synthesized on a DNA template in the cell nucleus. Pre-mRNA can follow two distinct cellular pathways. In the upward direction, pre-mRNA gives rise to 5′-3′ mRNA sequences through canonical splicing (a), which removes introns and generates a molecule to be exported to the cytoplasm for guiding protein synthesis. In the alternate downward direction, pre-mRNA produces circRNAs through back-splicing reactions (b). Intronic circRNAs (ciRNA) (c) are formed by a lariat-driven cyclization process that exclusively involves introns. Specific sequence elements adjacent to an exon, rich in guanine (G) and uracil (U) (depicted in blue), bind to an 11-nucleotide cytosine (C)-rich sequence (shown in red) near another exon. This binding allows evasion of the debranching reaction and prevents degradation by exonucleases. Reverse complementary sequences and/or RNA-binding proteins (RBP) (d) act to bring the nucleotide sequences into close proximity. This process facilitates the back-splicing reaction, leading to the generation of exonic circRNA (EciRNA) (e) or exon-intron circRNA (EIciRNA) (f). Abbreviations: mRNA, messenger RNA; pre-mRNA, precursor mRNA; ciRNA, intronic circRNA; EciRNA, exonic circRNA; EIciRNA, exon-intron circRNA; E, exon; I, intron; RBP, RNA-binding proteins.CC BY · PubMed Central
Figure 2 Alpha-synuclein (SNCA), circSNCA, and the cellular stressors acting on the neurodegenerative process of PD. (a) The CDS region of SNCA mRNA originates the (b) normal folded SNCA protein, which, under (c) oxidative stress, causes the formation of (d) SNCA aggregates. These aggregates induce toxicity and further neurodegeneration. The 3′UTR region of SNCA mRNA originates (e) circSNCA, which acts as a sponge for miR-7 (f,g), leading to an increase in pro-apoptotic proteins and neurodegeneration. Abbreviations: 5′UTR, 5′untranslated region; 3′UTR, 3′untranslated region; CDS, coding sequence.
Figure 2 Alpha-synuclein (SNCA), circSNCA, and the cellular stressors acting on the neurodegenerative process of PD. (a) The CDS region of SNCA mRNA originates the (b) normal folded SNCA protein, which, under (c) oxidative stress, causes the formation of (d) SNCA aggregates. These aggregates induce toxicity and further neurodegeneration. The 3′UTR region of SNCA mRNA originates (e) circSNCA, which acts as a sponge for miR-7 (f,g), leading to an increase in pro-apoptotic proteins and neurodegeneration. Abbreviations: 5′UTR, 5′untranslated region; 3′UTR, 3′untranslated region; CDS, coding sequence.CC BY · PubMed Central
Figure 3 Strategies for targeting circRNAs. The four most common methods to modify circRNA content include viral and non-viral vectors, AONs, and small-interfering RNAs (siRNAs). On the left, engineered viral vectors with specific cassettes enter the cell without carriers and overexpress a specific circRNA. The other strategies for targeting circRNAs require a nanoparticle to carry nucleic acids (siRNA, AON and plasmid) across the plasma membrane into the cytosol, which then form endocytic vesicles. Upon vesicle disruption, the plasmids or oligonucleotides are free to perform their functions. Plasmids are circular double-stranded DNA sequences engineered to overexpress single-stranded RNA that can circularize and form the intended circRNA, providing gain-of-function effects similar to viral vectors. In contrast, loss-of-function effects are achieved with AONs, single-stranded RNA sequences that bind through Watson–Crick base pairing to complementary nucleotides in circRNA, blocking protein interaction sites. Additionally, siRNAs are short double-stranded RNA molecules that trigger RNAi mechanisms involving the RISC complex, leading to circRNA cleavage. Abbreviations: circRNA, circular RNA; siRNA, small-interfering RNA; RISC, RNA-inducing silencing complex.
Figure 3 Strategies for targeting circRNAs. The four most common methods to modify circRNA content include viral and non-viral vectors, AONs, and small-interfering RNAs (siRNAs). On the left, engineered viral vectors with specific cassettes enter the cell without carriers and overexpress a specific circRNA. The other strategies for targeting circRNAs require a nanoparticle to carry nucleic acids (siRNA, AON and plasmid) across the plasma membrane into the cytosol, which then form endocytic vesicles. Upon vesicle disruption, the plasmids or oligonucleotides are free to perform their functions. Plasmids are circular double-stranded DNA sequences engineered to overexpress single-stranded RNA that can circularize and form the intended circRNA, providing gain-of-function effects similar to viral vectors. In contrast, loss-of-function effects are achieved with AONs, single-stranded RNA sequences that bind through Watson–Crick base pairing to complementary nucleotides in circRNA, blocking protein interaction sites. Additionally, siRNAs are short double-stranded RNA molecules that trigger RNAi mechanisms involving the RISC complex, leading to circRNA cleavage. Abbreviations: circRNA, circular RNA; siRNA, small-interfering RNA; RISC, RNA-inducing silencing complex.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Metadata

Authors
Titze-de-Almeida, S. S. S., & Titze-de-Almeida, R.
Affiliations
Universidade de Brasília (BR)
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2023-06-20
Volume
15
Issue
8
Pages
2035-2035
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4385349756
Cited by
26
References
1
Citations by year
2026: 5 · 2025: 11 · 2024: 9
FWCI
0.66
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Circular RNAs in diseases
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords
circular RNA, Parkinson's disease, circHIPK3, neurodegenerative diseases, RNA interference, antisense oligonucleotides, CRISPR-Cas, off-target effects, neuroprotection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progress in circRNA-Based Therapy in Experimental Parkinson’s Disease. https://app.cochat.ai/papers/10.20944/preprints202306.1406.v1
The paper
Titze-de-Almeida, S. S. S., & Titze-de-Almeida, R. (2023). Progress in circRNA-Based Therapy in Experimental Parkinson’s Disease. Pharmaceutics. https://doi.org/10.20944/preprints202306.1406.v1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.